Accurate prognostication is essential when selecting the most appropriate adjuvant therapy following surgery for early breast cancer. A number of predictive models are now available to help estimate the survival for individual patients, including the Nottingham Prognostic Index (NPI), Adjuvant and Predict, and to date, these have all been based on known pathological prognostic factors including tumour size, tumour grade and lymph node status. The NPI, first described in1982 ([@bib17]), has been prospectively validated ([@bib39]; [@bib7]) and more recently updated ([@bib1]) to provide accurate survival estimates following breast cancer surgery, including individual survival estimates ([@bib2]). The introduction of Adjuvant!, a web-based ([www.adjuvantonline.com](http://www.adjuvantonline.com)) prognostication tool, in 2001 ([@bib31]) went a step further by also providing absolute treatment benefits for hormone therapy and chemotherapy by applying risk reductions from the [@bib9], [@bib10]) to breast cancer-specific mortality estimates based on the Surveillance Epidemiology and End Results Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)). This model has been validated in case cohorts from British Columbia ([@bib24]), the Netherlands ([@bib22]) and the United Kingdom ([@bib5]).

Prognostication is becoming more sophisticated, and additional prognostic and predictive factors need to be considered in any current prognostic and treatment benefit model. There is a growing body of evidence to show that screen detection confers an additional survival benefit beyond stage shift and also reduces the risk of systemic recurrence when compared with symptomatic cancers of a similar stage ([@bib19]; [@bib34]). Recent studies have shown that the majority of the survival advantage associated with breast screening can be explained by this shift to an earlier stage at diagnosis, and more favourable prognostic factors ([@bib8]), but approximately 25% of the survival advantage is still unexplained ([@bib42]). These findings were recently confirmed in a data set from the Netherlands in which screen detection was associated with a 26 and 38% reduction in all-cause and breast cancer-specific mortality, respectively ([@bib23]). The authors from this paper concluded that method of detection should be taken into account when estimating individual prognosis.

Predict is an online prognostication and treatment benefit tool developed in the United Kingdom, which is based on 5694 women diagnosed in East Anglia from 1999 to 2003 ([@bib40]). The model includes mode of detection and provides 5- and 10-year survival estimates as well as treatment benefit predictions at both time points, and it has been validated in an independent case cohort from the United Kingdom and more recently in a British Columbia data set wherein it was also compared with Adjuvant! ([@bib41]). This comparison showed that Predict and Adjuvant! provide accurate overall and breast cancer-specific survival (BCSS) estimates that were comparable. However, the Predict estimates did not utilise the mode of detection component of the model as the mode of detection was not available for the British Columbia cohort. Moreover, Adjuvant! does not take account of the mode of detection. Predict was slightly better calibrated for breast cancer-specific mortality with predicted deaths being within 3.4% of observed deaths compared with 6.7% for Adjuvant!. Both models showed good discrimination with similar area under the receiver-operator characteristic curve (AUC; 0.723 *vs* 0.727 for Predict and Adjuvant, respectively). Predict is now available online at [www.predict.nhs.uk](http://www.predict.nhs.uk).

The aim of this study was to incorporate the prognostic effect of HER2 status into Predict (hereafter referred to as Predict+), and to compare the 10-year survival estimates from Predict+ with Predict, Adjuvant! and the observed 10-year outcome from the British Columbia data set.

Methods
=======

Prognostic effect of tumour HER2 status
---------------------------------------

Estimates for the prognostic effect of HER2 status were based on an analysis of data from the Breast Cancer Association Consortium (BCAC). Pathology data from 12 of these studies has been previously published ([@bib3]) and the analysis was updated to include data from another 3 studies excluded from the previous publication because of missing data on basal markers that is not relevant for this analysis ([Table 1](#tbl1){ref-type="table"}). However, as the validation cohort for this study overlaps substantially with the British Columbia Cancer Agency (BCCA) case series published in [@bib3], this case series was excluded from the BCAC data re-analysis. In addition, all patients diagnosed since 2004 were excluded, to exclude patients likely to have been treated with trastuzumab. In total, HER2 data were available for 10 179 cases (7278 ER-positive and 2931 ER-negative, [Table 2](#tbl2){ref-type="table"}) for whom data were also available for age at diagnosis, tumour size (⩽2, 2--4.9 and 5+ cm), tumour grade and nodal status. We estimated the hazard ratio for HER2-positive disease compared with HER2-negative disease using a Cox proportional hazards model stratified by study and adjusted for size, grade and nodal status. Separate regression models were used for ER-positive and ER-negative cases. As we have shown previously ([@bib3]), the hazard ratio for HER2-positive disease decreases over time in women with ER-positive breast cancer, so the log hazard ratio was modelled to vary linearly with time. The effect of HER2 in women with ER-negative breast cancer is not time-dependent.

The hazard ratios estimated from the BCAC data set were then used to modify Predict, which is also based on a Cox proportional hazards models. However, Predict was developed using a case cohort of breast cancer cases of unknown HER2 status, and so the underlying baseline hazard is representative of cases of average HER2 status. The HER2 hazard ratio estimates based on the BCAC data are for HER2-positive cases compared with HER2-negative cases, and so these were rescaled to give an average hazard ratio of unity using an estimated prevalence of HER2 of 9% in ER-positive cases and 25% in ER-negative cases. The applied hazard ratios for ER-positive cases are shown in [Table 3](#tbl3){ref-type="table"}. A fixed hazard ratio of 0.93 for HER2--negative cases and 1.27 for HER2--positive cases compared with HER2 unknown cases was applied to the baseline hazard of the ER-negative model.

Validation study population
---------------------------

We used the same case cohort from British Columbia, Canada, which we used to validate the original version of Predict. The data set has previously been described ([@bib24]), but, in brief, includes data from 1653 patients with information on HER2 status out of a total of 3140 patients with stage I or II invasive breast cancer diagnosed in British Columbia, Canada, from 1989 to 1993, who were identified from the Breast Cancer Outcomes Unit (BCOU) of the BCCA. The BCOU prospectively records demographical information, pathological information, staging, initial treatment and outcome information including first loco-regional and distant relapse, as well as date and cause of death. Outcome data were reported annually by the treating oncologist, family physician or by monthly death certificate flagging through the British Columbia Cancer Registry and Department of Vital Statistics for British Columbia.

Information obtained from the BCOU database included age at diagnosis, sex, menopausal status, year of diagnosis, histology (ductal, lobular, other), histological grade, tumour size, number of lymph nodes sampled and number of lymph nodes positive, lymphovascular invasion status, ER status, HER2 status, type of local therapy (wide local excision, mastectomy, radiotherapy) and type of adjuvant systemic therapy (none, chemotherapy, endocrine therapy, both). The HER2 status was evaluated using TMAs as previously described ([@bib6]). Chemotherapy regimens were categorised as four cycles of doxorubicin plus cyclophosphamide; 6 months of cyclophosphamide, methotrexate and fluorouracil, or other chemotherapy during this time period. None of these patients received trastuzumab.

Study endpoints were overall survival (OS) and BCSS. Of 1653 cases used in this analysis, cause of death was unknown in 5, and so 1648 cases were used for the analysis of BCSS. Ten-year-predicted OS and BCSS were calculated for each patient using Predict+, Predict and Adjuvant! (standard version 8) by investigators blinded to the actual outcome data for each patient after entry of patient age, tumour size, number of positive nodes, tumour grade, ER status, HER2 status (Predict+ only) and adjuvant systemic therapy. The default comorbidity setting of 'minor symptoms\' and the chemotherapy option chosen was 'anthracycline-containing; ⩾4 cycles\' were used in Adjuvant!. The 'second-generation\' chemotherapy option (anthracycline-containing regimens) was used in Predict+ and Predict. The mode of detection input was not used in Predict or Predict+, as this information was not available in the British Columbia data set. Ten-year-predicted OS and BCSS from Predict+, Predict and Adjuvant were compared with observed 10-year OS and BCSS.

Model calibration is a comparison of the predicted mortality estimates from each model with the observed mortality. In addition to comparing calibration in the complete data set, we evaluated calibration within strata of other prognostic variables. We also evaluated calibration within quartiles of predicted mortality. A goodness-of-fit test was carried out by using a *χ*^2^-test based on the observed and predicted number of events (4 d.f.). Model discrimination was evaluated by calculating the AUC calculated for 10-year breast cancer-specific and overall mortality. This is a measure of how well the models identify those patients with worse survival. The AUC is the probability that the predicted mortality from a randomly selected patient who died will be higher than the predicted mortality from a randomly selected survivor.

Results
=======

The calibration of Predict for both all-cause mortality and for breast cancer-specific mortality was improved by the incorporation of HER2 status. Adjuvant! performed slightly better than Predict and Predict+ for all-cause mortality, but both Predict and Predict+ outperformed Adjuvant! for breast cancer-specific mortality. All three models slightly underestimated the observed number of deaths. The total number of deaths predicted by Adjuvant was within 6.1% of that observed (492 *vs* 524, *P*=0.16) compared with 8.8% for Predict (478 *vs* 524, *P*=0.04) and 8.4% for Predict+ (480 *vs* 524, *P*=0.05). The total number of breast cancer-specific deaths predicted by Adjuvant was within 14% of that observed (311 *vs* 360, *P*=0.01) compared with 3.6% for Predict (347 *vs* 360, *P*=0.49) and 2.5% for Predict+ (351 *vs* 360, *P*=0.60). [Table 4](#tbl4){ref-type="table"} shows the observed and predicted all-cause 10-year OS by various clinico-pathological sub-groups. All models performed well in most subgroups. Notable exceptions were the performance in women aged 20--35 years, in which all three models underpredicted the actual number of deaths by 32%, and in HER2-positive cases, in which Adjuvant and Predict underestimated the number of deaths by close to 20% compared with just 9% for Predict+. None of these differences were statistically significant (*P*\>0.05). We also compared the predicted mortality with that observed for women in each quartile of predicted risk. Calibration was good for Adjuvant! across all risk categories (goodness-of-fit, *P*=0.51), and reasonable for Predict+ (goodness-of-fit, *P*=0.042) and Predict (goodness-of-fit, *P*=0.032) ([Figures 1A--C](#fig1){ref-type="fig"}). [Table 5](#tbl5){ref-type="table"} shows the observed 10-year breast cancer-specific mortality compared with that predicted by Predict+, Predict and Adjuvant. Again, each model performed well across most subgroups, except in women aged 20--35 years wherein they all underpredicted the actual number of deaths by 32% (*P*\>0.05). In HER2-positive patients, the total number of breast cancer-specific deaths predicted by Predict+ was within 5% of observed (71 *vs* 75, *P*=0.64) compared with 20% for Predict (*n*=60 *vs* 75, *P*=0.08) and 29% for Adjuvant (53 *vs* 75, *P*=0.01). Calibration across the quartiles of predicted breast cancer risk was good for Predict+ (goodness-of-fit, *P*=0.11) and Predict (goodness-of-fit, *P*=0.068), and reasonable for Adjuvant! (goodness-of-fit, *P*=0.001) ([Figures 1D--F](#fig1){ref-type="fig"}). Model discrimination was similar for all three models with AUCs for breast cancer-specific mortality of 0.665, 0.661 and 0.649 for Predict+, Predict and Adjuvant!, respectively.

Discussion
==========

Predict was developed using a flexible, Cox proportional hazards model that enables the easy incorporation of additional prognostic factors using external estimates of the prognostic effect of such a factor. We have used this flexibility to incorporate the prognostic effect of HER2 derived from a large multi-centre study. A key feature of Predict, and one that differentiates it from Adjuvant!, is that it uses different underlying models for ER-positive and ER-negative disease. This is particularly important as the effect of other prognostic variables is often different according to ER status. This difference is particularly marked for HER2 status, where the effect of HER2 is strongly time-dependent in ER-positive cases but not for ER-negative cases. Our results confirm that the inclusion of HER2 status in the clinical prognostication tool Predict improves both model discrimination and calibration. The improvement in model fit was most pronounced in the HER2-positive subset of patients and was particularly marked for breast cancer-specific mortality. Given that it is breast cancer-specific mortality that is reduced by adjuvant therapy ([@bib9], [@bib10]), it is likely that improved model performance will lead to more accurate predictions of the absolute benefit of treatment. Adjuvant! performed better than either Predict or Predict+ for overall mortality. This might be expected as the background mortality data on which Adjuvant! is based are from North America, whereas Predict is based on background mortality data from the United Kingdom.

The weaknesses of our study also need to be considered in interpreting our results. There were some missing data for the BCAC cohorts used to derive the HER2-specific hazard ratios and for the BCOU cohort. Data were missing for multiple reasons, but the major reason was because of unavailability of archival pathology material. Although it is possible that there is some selection bias in the missing data -- for example, pathology material is more likely to be unavailable for small tumours -- any bias is unlikely to be large. This notion is supported by the results of the validation in the independent data from the BCOU cohort. As we have described previously, none of the models performed very well in the youngest age group. The reasons for this are unclear, but probably reflect the fact that the data on which the models were based included relatively small numbers of patients in this age group.

The online version of Predict includes survival estimates and treatment benefit at 5 and 10 years post diagnosis. Four clinical trials have now reported on the benefit of trastuzumab therapy -- FinHER ([@bib18]), HERA ([@bib36]), B31/N9831 ([@bib32]; [@bib26]) and BCIRG006 ([@bib35]). The relative reduction in the all-cause mortality has ranged from 0.33 to 0.45. Two studies reported results stratified by tumour hormone-receptor status neither of which found evidence for heterogeneity ([@bib32]; [@bib36]; [@bib26]). The new version of Predict+, including trastuzumab benefit at 5 years is available at [www.predict.nhs.uk](http://www.predict.nhs.uk).

One of the key advantages of the Predict models is that they include mode of detection as one of the input parameters. As previously discussed, screen detection appears to confer an additional survival advantage over and above known prognostic factors. Unfortunately, as screening data was not available in the British Columbia data set, it was not possible to use this feature when running the Predict models, so the default setting was 'unknown\' for all patients. Thus, we cannot estimate the performance of the Predict models if the mode of detection were known. However, it is very likely that model performance would improve with the addition of mode-of-detection data. In addition, a recent publication has called for the mode of detection to be taken into account when deciding optimal adjuvant therapy for an individual patient ([@bib23]). Predict+ can now provide such a model with the added benefit of the inclusion of HER2 status as well as the absolute treatment benefit of trastuzumab at 5 years. Further validations of Predict+ in data sets where the mode of detection, HER2 status and trastuzumab treatment are recorded are planned in the near future.

This study reports the first successful inclusion of HER2 status in a prognostic model (Predict+) based on known clinical and pathological factors. The study has demonstrated a marked improvement in 10-year BCSS estimates using Predict+ compared with the original Predict model for HER2-positive patients. Both Predict models provide better BCSS estimates than Adjuvant! in HER2-positive patients in this data set. This improvement in BCSS prognostication for HER2-positive patients was not achieved at the expense of the HER2-negative cohort, wherein both Predict and Predict+ performed better than Adjuvant. Predict+ also provided better breast cancer-specific mortality estimates that Predict and Adjuvant. This is extremely important for optimal model function, as it is the breast cancer-specific mortality that is reduced by the relative risk reductions of adjuvant therapy, and this improvement in model performance by Predict+ should lead to more accurate absolute treatment benefit predictions for individual patients.
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###### Description of participating studies

  **Study**                                                   **Country**       **Case ascertainment**   **Case definition**                                                                                                                                                                                                                                                                                                                                                                   **Age range (years)**  **References**
  ----------------------------------------------------------- ----------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------- ------------------------------
  Amsterdam Breast Cancer Study                               The Netherlands   Hospital-based           All cases of operable, invasive cancer diagnosed from 1974--1994 in four Dutch hospitals. Familial non-BRCA1/2 cases \<50 from the Clinical Genetic Centre at the Netherlands Cancer Institute                                                                                                                                                                                               23--50          [@bib33]
  Bavarian Breast Cancer Case--Control Study                  Germany           Hospital-based cases     Consecutive, unselected cases with invasive breast cancer recruited at the University Breast Centre, Franconia in Northern Bavaria during 2002--2006                                                                                                                                                                                                                                         27--86          [@bib13]
  Helsinki Breast Cancer Study                                Finland           Hospital-based           \(1\) Consecutive cases (883) from the Department of Oncology, Helsinki University Central Hospital 1997--1998 and 2000, (2) consecutive cases (986) from the Department of Surgery, Helsinki University Central Hospital 2001--2004, (3) familial breast cancer patients (536) from the Departments of Oncology and Clinical Genetics, Helsinki University Central Hospital(1995)           22--96          [@bib37]; [@bib20]; [@bib12]
  Jewish General Hospital                                     Canada            Hospital-based           Ashkenazi Jewish women diagnosed with non-metastatic, invasive breast cancer at Jewish General Hospital, Montreal, between 1980 and 1995                                                                                                                                                                                                                                                     26--66          [@bib38]
  Kuopio Breast Cancer Study                                  Finland                                    Women seen at Kuopio University Hospital between 1990 and 1995 because of breast lump, mammographic abnormality, or other breast symptom, who were found to have breast cancer                                                                                                                                                                                                               23--92          [@bib16]
  Mayo Clinic Breast Cancer Study                             USA               Hospital-based           Incident cases residing in six states (MN, WI, IA, IL, ND, SD) seen at the Mayo Clinic in Rochester, MN, from 2002--2005                                                                                                                                                                                                                                                                     22--89          [@bib25]
  Melbourne Collaborative Cohort Study                        Australia         Cohort                   Incident cases diagnosed within the Melbourne Collaborative Cohort Study during the follow-up from baseline (1990--1994) to 2004 of the 2 4469 participating women                                                                                                                                                                                                                           30--82          [@bib15]
  Nottingham Breast Cancer Case Series                        UK                Hospital-based           Primary operable breast carcinoma patients presenting from 1986 to 1998, and entered into the Nottingham Tenovus Primary Breast Carcinoma Series                                                                                                                                                                                                                                             26--93          [@bib30]
  Oulu Breast Cancer Study                                    Finland           Hospital-based           Consecutive incident cases diagnosed at the Oulu University Hospital, 2000--2004                                                                                                                                                                                                                                                                                                             28--92          [@bib11]
  NCI Polish Breast Cancer Study                              Poland            Population-based         Incident cases from 2000--2003 identified through a rapid identification system in participating hospitals covering ∼90% of all eligible cases; periodic check against the cancer registries in Warsaw and Łódź to assure complete identification of cases                                                                                                                                   27--75          [@bib14]
  Sheffield Breast Cancer Study                               UK                Hospital-based           Women with pathologically confirmed breast cancer, recruited from surgical outpatient clinics at the Royal Hallamshire Hospital, Sheffield, 1998--2002; cases are a mixture of prevalent and incident disease                                                                                                                                                                                29--93          [@bib27]; [@bib21]
  Study of Epidemiology and Risk factors in Cancer Heredity   UK                Population-based         Two groups of cases identified through East Anglian Cancer Registry: (1) prevalent cases diagnosed age \<55 years from 1991--1996 and alive when study started in 1996; (2) incident cases diagnosed age \<70 years diagnosed after 1996                                                                                                                                                     23--69          [@bib4]
  University of British Columbia Breast Cancer Trials         Canada            Hospital-based           Women with stage I to III breast cancer, who participated in four different British Columbia Cancer Agency clinical trials between 1970 and 1990, and all received chemotherapy                                                                                                                                                                                                              22--90          [@bib28]; [@bib29]
  Vancouver General Hospital                                  Canada            Hospital-based           Women with primary breast cancer, who underwent surgery at Vancouver General Hospital 1975--1995                                                                                                                                                                                                                                                                                             28--91          [@bib38]

###### Number of cases by study, ER status and HER2 status

           **ER-positive**   **ER-negative**                                                        
  -------- ----------------- ----------------- ----- -------- ------ ------ -------- ----- -------- ------
  ABCS     512               \(87\)            74    \(13\)   586    231    \(77\)   69    \(23\)   300
  BBCC     585               \(88\)            77    \(12\)   662    164    \(73\)   62    \(27\)   226
  HEBCS    173               \(88\)            23    \(12\)   196    37     \(77\)   11    \(23\)   48
  JGH      166               \(94\)            11    \(6\)    177    77     \(79\)   21    \(21\)   98
  KBCS     281               \(93\)            20    \(7\)    301    59     \(67\)   29    \(33\)   88
  MCBCS    386               \(84\)            71    \(16\)   457    67     \(77\)   20    \(23\)   87
  MCCS     307               \(93\)            24    \(7\)    331    99     \(76\)   31    \(24\)   130
  NOBCS    1006              \(96\)            40    \(4\)    1046   346    \(82\)   76    \(18\)   422
  OBCS     390               \(91\)            39    \(9\)    429    72     \(68\)   34    \(32\)   106
  PBCS     656               \(95\)            34    \(5\)    690    289    \(80\)   71    \(20\)   360
  SBCS     201               \(93\)            15    \(7\)    216    70     \(84\)   13    \(16\)   83
  SEARCH   1447              \(91\)            135   \(9\)    1582   334    \(75\)   113   \(25\)   447
  UBC      299               \(76\)            93    \(24\)   392    296    \(66\)   152   \(34\)   448
  VGH      201               \(94\)            12    \(6\)    213    42     \(72\)   16    \(28\)   58
  Total    6610              \(91\)            668   \(9\)    7278   2183   \(75\)   718   \(25\)   2901

Abbreviations: ABCS=Amsterdam Breast Cancer Study; BBCC=Bavarian Breast Cancer Case--Control Study; ER=oestrogen receptor; HEBCS=Helsinki Breast Cancer Study; HER2=human epidermal growth factor receptor-2; JGH=Jewish General Hospital; KBCS=Kuopio Breast Cancer Study; MCBCS=Mayo Clinic Breast Cancer Study; MCCS=Melbourne Collaborative Cohort Study; NOBCS=Nottingham Breast Cancer Case Series; OBCS=Oulu Breast Cancer Study; PBCS=NCI Polish Breast Cancer Study; SBCS=Sheffield Breast Cancer Study; SEARCH=Study of Epidemiology and Risk factors in Cancer Heredity; UBCBCT=University of British Columbia Breast Cancer Trials; VGH=Vancouver General Hospital.

###### Hazard ratio by HER2 status by time since diagnosis in ER-positive breast cancer

       **HER2 status**          
  ---- ----------------- ------ ------
  1    1                 1.84   0.95
  2    1                 1.70   0.95
  3    1                 1.58   0.96
  4    1                 1.47   0.97
  5    1                 1.36   0.97
  6    1                 1.26   0.98
  7    1                 1.17   0.99
  8    1                 1.08   0.99
  9    1                 1.01   1.00
  10   1                 0.93   1.01

Abbreviations: ER=oestrogen receptor; HER2=human epidermal growth factor receptor-2.

Weighted average hazard ratio for HER2+ and HER2− =1.

###### Observed and predicted 10-year all-cause mortality by demographical, pathological and treatment characteristics

                               **Deaths**               
  --------------------- ------ ------------ ----- ----- -----
  *Age group (years)*                                   
   20--35               55     22           15    15    15
   36--50               492    120          112   119   119
   51--65               523    152          133   132   133
   66--75               433    153          153   141   142
   76+                  150    76           79    71    71
                                                         
  *Menopausal status*                                   
   Pre-                 520    135          121   128   128
   Post                 1089   380          360   339   341
   Peri-/unknown        44     8            10    11    11
                                                         
  *Morphology*                                          
   Ductal               1489   479          440   428   432
   Lobular              132    38           43    40    40
   Other                32     5            8     8     8
                                                         
  *Grade*                                               
   1                    104    22           19    15    15
   2                    778    208          203   176   177
   3                    694    269          247   265   268
   Unknown              77     24           23    20    20
                                                         
  *LV invasion*                                         
   Negative             868    233          230   218   218
   Positive             715    262          239   238   241
   Unknown              70     26           22    20    20
                                                         
  *Node status*                                         
   Negative             976    235          230   215   216
   Positive             677    288          262   262   265
                                                         
  *Tumour size*                                         
   1--10                210    40           39    40    40
   11--20               745    196          189   186   187
   21--50               698    287          264   251   253
                                                         
  *ER status*                                           
   ER−                  350    123          124   129   130
   ER+                  1303   400          367   348   350
                                                         
  *Local Rx*                                            
   BCS+RT               814    200          205   200   200
   Mast+RT              169    77           74    77    78
   Mast                 670    246          213   201   202
                                                         
  *Systemic Rx*                                         
   None                 660    175          170   161   162
   Hormone              526    201          188   175   176
   Chemo                317    96           93    97    98
   Both                 150    51           41    43    44
                                                         
  *HER2*                                                
   Negative             1450   434          420   405   398
   Positive             203    90           72    73    82
                                                         
  Total                 1653   524          492   478   480

Abbreviations: BCS=breast conserving surgery; ER=oestrogen receptor; HER2=human epidermal growth factor receptor-2; LV=lymphovascular; RT=radiotherapy.

The sum of the predicted events within categories may differ from the sum of the observed events because of rounding errors in the predicted events.

###### Observed and predicted 10-year breast cancer-specific mortality by demographical, pathological and treatment characteristics

                               **Deaths from breast cancer**               
  --------------------- ------ ------------------------------- ----- ----- -----
  *Age group*                                                              
   20--35               55     22                              15    15    15
   36--50               492    118                             102   110   110
   51--65               522    102                             96    106   108
   66--75               430    88                              76    86    87
   76+                  149    30                              23    31    31
                                                                            
  *Menopausal status*                                                      
   Pre−                 520    133                             110   118   119
   Peri-/Unknown        1085   221                             192   220   222
   Post−                43     6                               9     9     9
                                                                            
  *Morphology*                                                             
   Ductal               1485   340                             281   314   318
   Lobular              131    18                              24    26    26
   Other                32     2                               7     7     7
                                                                            
  *Grade*                                                                  
   1                    104    4                               5     5     5
   2                    775    133                             108   104   104
   3                    693    206                             183   225   228
   Unknown              76     17                              15    14    14
                                                                            
  *LV invasion*                                                            
   Negative             864    144                             129   142   142
   Positive             714    196                             168   190   193
   Unknown              70     18                              13    14    14
                                                                            
  *Node status*                                                            
   Negative             972    132                             117   128   129
   Positive             676    228                             194   219   221
                                                                            
  *Tumour size*                                                            
   1--10                210    22                              14    21    21
   11--20               741    118                             101   121   122
   21--50               697    220                             196   205   208
                                                                            
  *ER status*                                                              
   ER−                  350    104                             102   113   114
   ER+                  1298   256                             209   234   236
                                                                            
  *Local Rx*                                                               
   BCS+RT               810    140                             128   142   142
   Mast+RT              169    59                              59    69    70
   Mast                 669    161                             124   137   139
                                                                            
  *Systemic Rx*                                                            
   None                 658    100                             88    99    99
   Hormone              523    121                             102   117   118
   Chemo                317    94                              86    92    93
   Both                 150    45                              36    40    40
                                                                            
  *HER2*                                                                   
   Negative             1445   285                             258   287   280
   Positive             203    75                              53    60    71
                                                                            
  Total                 1648   360                             311   347   351

Abbreviations: BCS=breast conserving surgery; ER=oestrogen receptor; HER2=human epidermal growth factor receptor-2; LV=lymphovascular; RT=radiotherapy.

The sum of the predicted events within categories may differ from the sum of the observed events because of rounding errors in the predicted events.
